Amgen Inc. Stock

Dividend stocks are potent instruments for building wealth. A staggering 85% of the S&P 500's total returns since 1960 have emanated from dividend payouts, according to a report by Hartford Funds.

A

Amgen (NASDAQ: AMGN) is one of the top drugmakers in the world, with a market value north of $140 billion. The company has been expanding its business via acquisitions in recent years as it looks to

The biotech industry can be attractive for several reasons. Many leading biotechs develop innovative, life-saving therapies, a business that will only be phased out once we find an all-purpose cure

Biotech giant Amgen (NASDAQ: AMGN) isn't starting the year on a strong note. The company's shares are down by 5% since Jan. 1. It has dealt with some issues lately, especially subpar financial

Amgen (NASDAQ: AMGN) is one of the largest drug manufacturers in the world, with a market cap of more than $150 billion. It pays a dividend, has been growing steadily over the years, and has many

Amgen (NASDAQ: AMGN) is well on its way to producing a medicine for obesity that could one day rival the blockbuster weight-loss drugs like Wegovy and Zepbound made by the segment's monarchs, Novo

The biotech industry has been in a slump over the past two years, but Amgen (NASDAQ: AMGN) has performed comparatively well. That's not to say this leading drugmaker hasn't had its share of issues

As dividend investors know, there's an upside to investing in a big pharmaceutical business like Amgen (NASDAQ: AMGN) for dividend income. It likely has the resources and proven capabilities that'll

Cancer bites, but Amgen (NASDAQ: AMGN) is going to keep biting back. In fact, it's currently developing a handful of oncology medicines that it describes as bispecific T-cell engager therapies, or

Clinical-stage biotech Vera Therapeutics (NASDAQ: VERA) had a week to remember on the stock market. Over the past five trading days, according to data compiled by S&P Global Market Intelligence, the

This year hasn't been kind to biotech stocks, which as a group haven't kept pace with the broader market. The performance of the SPDR S&P Biotech ETF makes that clear. Leading drugmaker Amgen

The human genome project, which was completed in 2003, marked a milestone for biotechnology. It opened the door for the creation of hundreds of medicines based on biology, which have improved the

It's been a rough year for the biotech industry, which as a whole has substantially lagged the broader market. Just look at the performance of the SPDR S&P Biotech ETF, an industry benchmark. What's